GB2243548A - Therapeutic nasal drops containing sulphonamides - Google Patents
Therapeutic nasal drops containing sulphonamides Download PDFInfo
- Publication number
- GB2243548A GB2243548A GB9009852A GB9009852A GB2243548A GB 2243548 A GB2243548 A GB 2243548A GB 9009852 A GB9009852 A GB 9009852A GB 9009852 A GB9009852 A GB 9009852A GB 2243548 A GB2243548 A GB 2243548A
- Authority
- GB
- United Kingdom
- Prior art keywords
- hydrochloride
- concentration
- products
- sympathomimetic
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Nose drops for treating local nasal infections contain a sulphonamide, preferably sodium sulphacetamide in aqueous solution. The solutions may also contain a sympathomimetic nasal decongestant and an anti-inflammatory corticosteroid.
Description
COMPOSITIONS OF SOME THERAPEUTIC ADVANTAGE PREPARED FROM A COMBINATION
OF AN ANTISEPTIC AGENT WITH A SYMPATHOMIMETIC COMPOUND IN THE FORM OF
NOSE DROPS
This invention relates to a novel composition of therapeutic significance prepared from a combination of an antiseptic agent with a sympathomimetic compound in the form of nose drops.
Previously, the treatment of notoriously reoccurring ailments such as rhinitis, sinusitis, hay fever, infected inflammatory nasal conditions, nasal congestion associated with infection and the nasal carriage of staphlococci has generally consisted of long term systemic oral antibiotic courses which are unpracticable due to the long term and frequent therapeutic dosages of antibiotic that need to be taken. Many people are known to suffer side effects when on frequent antibiotic courses and resistance by bacteria to long term oral administration of antibiotics is well documented.
It is therefore a principal object of this invention to provide a locally acting product of therapeutic significance prepared from an antiseptic agent in combination with sympathomimetic compounds with or without the addition of corticosteroid anti-inflammatory agents in the form of nose drops for the treatment of rhinitis, sinusitis, hay fever, infected inflammatory nasal conditions, nasal congestion associated with infection and the nasal carriage of bacteria.
Accordingly, the above object has been achieved by using the antiseptic agent sodium sulphacetamide in concentrations of 1 - 20 % with or without xylometazoline hydrochloride or oxymetazoline hydrochloride or tetrahydrozoline hydrochloride or tramozoline hydrochloride or any other sympathomimetic compounds in a concentration of 0.001 % to 2.0 %. The preferable concentration of the antiseptic agent is between 4.0 and 7.0 %. Sodium sulphacetamide is an antiseptic that has commonly been used in eye drops with an undisputed safety record for the last forty years. These eye drops have contained sodium sulphacetamide in a concentration of 10.0 to 30.0 % in an aqueous solution.
The inclusion of a sympathomimetic compound in the formula is due to its action as a vasoconstrictor. It helps to reduce inflammation and lowers congestion in nasal mucous membranes. The percentage preferred in this formula is about 25.0 % of the standard naphazoline nasal drop concentration.
Weaker strengths appear to provide a more sustained decongestant effect and also appear to minimise the rebound effect.
In this invention the preferred strength of sulphacetamide is 4.0 to 7.0 % which is not sufficient to irritate the nasal mucosa. Sulphacetamide is an effective bacteriostatic agent against a wide range of Gram-negative and Gram-positive bacteria.
The following examples illustrate the invention and the advantages thereof.
These examples are given by way of illustration only, and are not to be construed as limiting the invention in scope or in spirit, as many modifications will be apparent from this disclosure to those skilled in this art.
Example 1:
Sodium sulphacetamide 6.0 %
Xylometazoline hydrochloride 0.025 %
Example 2:
Sodium sulphacetamide 6.0 %
Oxymetazoline hydrochloride 0.0125 %
Example 3:
Sodium sulphacetamide 6.0 %
Tramazoline hydrochloride 0.025 %
Example 4:
Sodium sulphacetamide 6.0 %
Tetrahydrozoline hydrochloride 0.025 %
Example 5:
Sodium sulphacetamide 6.0 %
Antazoline sulphate 0.5 %
Naphazoline hydrochloride 0.1 %
Example 6:
Sodium sulphacetamide 6.0 %
Naphazoline hydrochloride 0.05 %
Betamethasone 0.1 %
Example 7:
Sodium sulphacetamide 6.0 %
Betamethasone 0.1 %
Claims (5)
- CLAIMS 1. Products for the treatment of rhinitis, sinusitis, hay fever, infected inflammatory nasal conditions, nasal congestion associated with infection derived from sulphonamide antiseptic agent with or without one or more sympathomimetic agents in the form of nose drops.
- 2. Products as in Claim 1 in which the antiseptic agent is sodium sulphacetamide in a concentration of 1.0 to 20.0 % in combination with sympathomimetic agent(s) in a concentration of 0.001 to 1.0 %.
- 3. Products as in Claims 1 & 2 to which a steroid compound is added in concentrations of 0.01 to 5.0 %.
- 4. Products as in Claim 1 comprising of any soluble sulponamide compound in a concentration of 1.0 to 20.0 % in combination with any sympathomimetic agent including xylometazoline hydrochloride, oxymetazoline hydrochloride, tramazoline hydrochloride, naphazoline hydrochloride, antazoline sulphate and tetrahydrozoline hydrochloride in a concentration of 0.001 to 2.0 %.
- 5. Products as in Claim 1 derived from sodium sulphacetamide in a concentration of 1.0 to 20.0 % without the addition of a sympathomimetic agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9009852A GB2243548B (en) | 1990-05-02 | 1990-05-02 | Nasal drops or spray containing sulphacetamide and a sympathomimetic imidazoline compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9009852A GB2243548B (en) | 1990-05-02 | 1990-05-02 | Nasal drops or spray containing sulphacetamide and a sympathomimetic imidazoline compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB9009852D0 GB9009852D0 (en) | 1990-06-27 |
| GB2243548A true GB2243548A (en) | 1991-11-06 |
| GB2243548B GB2243548B (en) | 1994-10-12 |
Family
ID=10675339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9009852A Expired - Lifetime GB2243548B (en) | 1990-05-02 | 1990-05-02 | Nasal drops or spray containing sulphacetamide and a sympathomimetic imidazoline compound |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2243548B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7108396B2 (en) | 2001-06-29 | 2006-09-19 | Permlight Products, Inc. | Modular mounting arrangement and method for light emitting diodes |
| US7114831B2 (en) | 1999-10-19 | 2006-10-03 | Permlight Products, Inc. | Mounting arrangement for light emitting diodes |
-
1990
- 1990-05-02 GB GB9009852A patent/GB2243548B/en not_active Expired - Lifetime
Non-Patent Citations (2)
| Title |
|---|
| THE EXTRA PHARMACOPOEIA, 26th EDITION, 1972, pp1745-1746, p.1764 * |
| THE PHARMACEUTICAL CODEX, 11th EDITION, 1979, PAGE 863 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7114831B2 (en) | 1999-10-19 | 2006-10-03 | Permlight Products, Inc. | Mounting arrangement for light emitting diodes |
| US7306353B2 (en) | 1999-10-19 | 2007-12-11 | Permlight Products, Inc. | Mounting arrangement for light emitting diodes |
| US7594740B2 (en) | 1999-10-19 | 2009-09-29 | Pemlight Products, Inc. | Mounting arrangement for light emitting diodes |
| US7108396B2 (en) | 2001-06-29 | 2006-09-19 | Permlight Products, Inc. | Modular mounting arrangement and method for light emitting diodes |
| US7387406B2 (en) | 2001-06-29 | 2008-06-17 | Permlight Products, Inc. | Modular mounting arrangement and method for light emitting diodes |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2243548B (en) | 1994-10-12 |
| GB9009852D0 (en) | 1990-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101463243B1 (en) | Antibiotic compositions for treatment of the eye ear and nose | |
| KR100211479B1 (en) | Intranasal formulations of 3-[2-(dimethylamino)ethyl]-n-methyl-1h-indole-5-methanesulphonamide | |
| ATE300282T1 (en) | ORAL LIQUID MUCOADHESIVE COMPOSITIONS | |
| ATE227978T1 (en) | ORAL LIQUID MUCOADHESIVE COMPOSITIONS | |
| LU91076I9 (en) | 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives | |
| CA2295061C (en) | Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin | |
| CA2321819A1 (en) | Xylitol compositions for treating upper respiratory conditions | |
| IL107157A0 (en) | Immunopotentiatory agents and pharmaceutical compositions comprising them | |
| RU94041223A (en) | Agent for motoneuron disease treatment | |
| CA2292359A1 (en) | Novel azalides and methods of making same | |
| ES2171590T7 (en) | Pharmaceutical preparation for the treatment of acute rhinitis that contains a sympathomimetic and pantothenol and / or pantothenic acid | |
| ITMI20001732A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MUCOSITES AND STOMATITIS | |
| CA2351429A1 (en) | 13-membered azalides and their use as antibiotic agents | |
| CA2136404A1 (en) | Mucoadhesive, therapeutic or hygienic solid composition for application on oral or nasal mucosa | |
| CA2280328A1 (en) | C11 carbamates of macrolide antibacterials | |
| US3232833A (en) | Heparin containing compositions | |
| WO2016159897A1 (en) | Potassium citrate suspension | |
| GB2243548A (en) | Therapeutic nasal drops containing sulphonamides | |
| WO2002064552A8 (en) | 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | |
| DE3579683D1 (en) | 1-SUBSTITUTED 6-FLUOR-7- (PYRROL-1-YL) -1,4-DIHYDRO-4-OXOCHINOLINE CARBONIC ACID DERIVATIVES, THEIR PRODUCTION AND USE AS MEDICINAL PRODUCTS. | |
| EP3567059A1 (en) | Substituted cyclodextrin-metal complexes and uses thereof | |
| ATE226429T1 (en) | ORAL LIQUID MUCOADHESIVE COMPOSITIONS | |
| JP2001131055A (en) | Liquid agent, removal of white cloudiness of liquid agent and acceleration of trans-mucous membrane absorption of liquid agent | |
| JPH0662442B2 (en) | Nasal drops | |
| AU2003248033A1 (en) | Antibiotic Compositions for Treatment of the Eye, Ear and Nose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE20 | Patent expired after termination of 20 years |
Expiry date: 20100501 |